{"component": "definition", "props": {"groups": [{"samples": [{"hash": "1aHl2HCT6VD", "uri": "/contracts/1aHl2HCT6VD#platform-technology", "label": "Products and Services Agreement", "score": 33.1902389526, "published": true}, {"hash": "bCGqvwTJLGk", "uri": "/contracts/bCGqvwTJLGk#platform-technology", "label": "Products and Services Agreement", "score": 32.749797821, "published": true}, {"hash": "9vT0O6pxtx8", "uri": "/contracts/9vT0O6pxtx8#platform-technology", "label": "Products and Services Agreement", "score": 31.7588710785, "published": true}], "snippet_links": [{"key": "form-of", "type": "definition", "offset": [21, 28]}, {"key": "from-time-to-time", "type": "clause", "offset": [126, 143]}, {"key": "in-all-respects", "type": "clause", "offset": [159, 174]}, {"key": "all-intellectual-property-rights", "type": "clause", "offset": [175, 207]}], "snippet": "means the executable form of the PressReader web building tools as such technology is revised, updated, enhanced and modified from time to time (and including in all respects all Intellectual Property Rights therein), as such exist from time to time;", "size": 7, "hash": "30a12b8c8f4742351c60cb2bad986ae0", "id": 1}, {"samples": [{"hash": "6bj6HbxlZcQ", "uri": "/contracts/6bj6HbxlZcQ#platform-technology", "label": "Non Exclusive Anticalin Platform Technology License Agreement (Pieris Pharmaceuticals, Inc.)", "score": 29.353181839, "published": true}, {"hash": "cng5n3EeYMo", "uri": "/contracts/cng5n3EeYMo#platform-technology", "label": "Non Exclusive License Agreement (Pieris Pharmaceuticals, Inc.)", "score": 29.3148536682, "published": true}, {"hash": "b7QowM8I7NU", "uri": "/contracts/b7QowM8I7NU#platform-technology", "label": "Non Exclusive License Agreement (Pieris Pharmaceuticals, Inc.)", "score": 28.2416152954, "published": true}], "snippet_links": [{"key": "anticalin-libraries", "type": "definition", "offset": [6, 25]}, {"key": "anticalin-selection", "type": "definition", "offset": [27, 46]}, {"key": "anticalin-expression", "type": "definition", "offset": [48, 68]}, {"key": "anticalin-characterization", "type": "definition", "offset": [70, 96]}, {"key": "anticalin-fusion-technology", "type": "definition", "offset": [98, 125]}, {"key": "anticalin-affinity-maturation", "type": "definition", "offset": [131, 160]}, {"key": "to-the-extent", "type": "clause", "offset": [174, 187]}], "snippet": "means Anticalin Libraries, Anticalin Selection, Anticalin Expression, Anticalin Characterization, Anticalin Fusion Technology, and Anticalin Affinity Maturation methods, all to the extent Controlled by Pieris.", "size": 6, "hash": "569485b4700220dd27829441ff4c281e", "id": 2}, {"samples": [{"hash": "kfKsqM6WGx", "uri": "/contracts/kfKsqM6WGx#platform-technology", "label": "Asset Purchase Agreement (Cerulean Pharma Inc.)", "score": 28.2142372131, "published": true}, {"hash": "dsFSSnfKRyJ", "uri": "/contracts/dsFSSnfKRyJ#platform-technology", "label": "Asset Purchase Agreement (Cerulean Pharma Inc.)", "score": 28.2142372131, "published": true}, {"hash": "ciAUPw70iA7", "uri": "/contracts/ciAUPw70iA7#platform-technology", "label": "License Agreement (Newlink Genetics Corp)", "score": 28.2142372131, "published": true}], "snippet_links": [{"key": "the-licensed-patent", "type": "clause", "offset": [6, 25]}, {"key": "sublicensed-patent-rights", "type": "definition", "offset": [38, 63]}, {"key": "licensed-know", "type": "definition", "offset": [69, 82]}], "snippet": "means the Licensed Patent Rights, the Sublicensed Patent Rights, the Licensed Know How and the Sublicensed Know How.", "size": 5, "hash": "7cb2eddcb40e649735f61d50055a2802", "id": 3}, {"samples": [{"hash": "ftIKnRsLLnF", "uri": "/contracts/ftIKnRsLLnF#platform-technology", "label": "Platform Technology Transfer, Collaboration and License Agreement (Codexis, Inc.)", "score": 31.591375351, "published": true}, {"hash": "kF08vS8Em9e", "uri": "/contracts/kF08vS8Em9e#platform-technology", "label": "Platform Technology Transfer, Collaboration and License Agreement (Codexis Inc)", "score": 25.8459949493, "published": true}, {"hash": "kYmsE8ESa3s", "uri": "https://www.codexis.com/investors/sec-filings/all-sec-filings/content/0001200375-14-000051/0001200375-14-000051.pdf", "label": "www.codexis.com", "score": 10.4291582108, "published": false}], "snippet_links": [{"key": "codexis-core-technology", "type": "definition", "offset": [14, 37]}, {"key": "codexis-enzymes", "type": "definition", "offset": [47, 62]}, {"key": "by-codexis", "type": "clause", "offset": [119, 129]}, {"key": "this-agreement", "type": "clause", "offset": [136, 150]}, {"key": "state-and-condition", "type": "clause", "offset": [161, 180]}, {"key": "skills-and-experience", "type": "clause", "offset": [257, 278]}, {"key": "field-of", "type": "definition", "offset": [286, 294]}, {"key": "subject-matter", "type": "definition", "offset": [535, 549]}, {"key": "codexis-documentation", "type": "definition", "offset": [558, 579]}, {"key": "codexis-materials", "type": "definition", "offset": [599, 616]}, {"key": "codexis-software", "type": "definition", "offset": [625, 641]}], "snippet": "means (a) the Codexis Core Technology, (b) the Codexis Enzymes and (c) the Codexis Libraries which are provided to GSK by Codexis under this Agreement in such a state and condition and in the detail which are necessary to enable a scientist with reasonable skills and experience in the field of protein engineering or protein biochemistry to use, identify, select, optimise, isolate, modify, engineer, research, develop, make, have made and/or import any Enzyme, in each of (a), (b) and (c), that (i) is described in, and embodies the subject matter of, the Codexis Documentation, and (ii) uses the Codexis Materials and the Codexis Software.", "size": 5, "hash": "513759369d4a924d709cab4548bdb5ab", "id": 4}, {"samples": [{"hash": "4FiAjMzK2LH", "uri": "/contracts/4FiAjMzK2LH#platform-technology", "label": "Collaboration and License Agreement (Citius Pharmaceuticals, Inc.)", "score": 26.8398361206, "published": true}, {"hash": "7ryFxg5lpn7", "uri": "/contracts/7ryFxg5lpn7#platform-technology", "label": "Collaboration and License Agreement (Citius Pharmaceuticals, Inc.)", "score": 26.7878170013, "published": true}, {"hash": "76XEeiNsRgx", "uri": "/contracts/76XEeiNsRgx#platform-technology", "label": "Collaboration and Development Agreement (Indevus Pharmaceuticals Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "the-technology", "type": "definition", "offset": [6, 20]}, {"key": "owned-by", "type": "definition", "offset": [35, 43]}, {"key": "date-hereof", "type": "clause", "offset": [60, 71]}, {"key": "relating-to", "type": "definition", "offset": [72, 83]}], "snippet": "means the technology developed and owned by Alpex as of the date hereof relating to fast-melt drug formulation processes and techniques.", "size": 4, "hash": "ae9a50051675aad3ad5dfaa0b95dedc7", "id": 5}, {"samples": [{"hash": "8H6FPbcR9qk", "uri": "https://www.sec.gov/Archives/edgar/data/1809122/000110465920089179/tm2016252d8_ex3-5.htm", "label": "Investment and Shareholders\u2019 Agreement (CureVac B.V.)", "score": 22.5790557861, "published": false}, {"hash": "eAztKusaiy4", "uri": "https://www.sec.gov/Archives/edgar/data/1809122/000110465920086354/tm2016252d12_ex3-5.htm", "label": "Investment and Shareholders\u2019 Agreement (CureVac B.V.)", "score": 22.5598907471, "published": false}], "snippet_links": [{"key": "the-corporation", "type": "clause", "offset": [6, 21]}, {"key": "development-of", "type": "clause", "offset": [39, 53]}, {"key": "infectious-diseases", "type": "definition", "offset": [115, 134]}, {"key": "comprised-of", "type": "definition", "offset": [158, 170]}, {"key": "delivery-technology", "type": "definition", "offset": [218, 237]}, {"key": "to-develop", "type": "definition", "offset": [248, 258]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [288, 314]}, {"key": "intent-of-the-parties", "type": "clause", "offset": [319, 340]}, {"key": "development-activities", "type": "definition", "offset": [349, 371]}, {"key": "clinical-development", "type": "definition", "offset": [411, 431]}], "snippet": "means the Corporation\u2019s technology for development of prophylactic and therapeutic mRNA vaccines and drugs against infectious diseases and vaccine adjuvants, comprised of long, non-coding RNA molecules and formulation/delivery technology necessary to develop the mRNA vaccines and drugs. For the avoidance of doubt the intent of the Parties is that development activities will include the full process from pre-clinical development to delivery.", "size": 4, "hash": "5b08634d732decaa3f695404b12f8826", "id": 6}, {"samples": [{"hash": "fR8O5nPse1c", "uri": "https://www.parlament.gv.at/dokument/XXVII/EU/191265/imfname_11391692.pdf", "label": "www.parlament.gv.at", "score": 19.0441436768, "published": false}, {"hash": "3dMwmls36w6", "uri": "https://www.europarl.europa.eu/doceo/document/TA-9-2024-0220_EN.pdf", "label": "www.europarl.europa.eu", "score": 18.8240413666, "published": false}], "snippet_links": [{"key": "the-development", "type": "clause", "offset": [125, 140]}, {"key": "manufacturing-process", "type": "definition", "offset": [142, 163]}, {"key": "quality-control", "type": "definition", "offset": [165, 180]}, {"key": "medicinal-products", "type": "definition", "offset": [196, 214]}, {"key": "prior-knowledge", "type": "clause", "offset": [248, 263]}, {"key": "scientific-principles", "type": "clause", "offset": [310, 331]}], "snippet": "means a technology or collection of technologies that is comprehensive, well-characterised, reproducible and used to support the development, manufacturing process, quality control, or testing of medicinal products or their components that rely on prior knowledge and are established under the same underlying scientific principles;", "size": 4, "hash": "d811a931adb0a7f73662f9c442382a5b", "id": 7}, {"samples": [{"hash": "gS5T7keWmHc", "uri": "/contracts/gS5T7keWmHc#platform-technology", "label": "License and Collaboration Agreement (Zealand Pharma a/S)", "score": 28.5099239349, "published": true}, {"hash": "6Z9oI484NlC", "uri": "/contracts/6Z9oI484NlC#platform-technology", "label": "License and Collaboration Agreement (Zealand Pharma a/S)", "score": 27.4558525085, "published": true}], "snippet_links": [{"key": "patent-right", "type": "clause", "offset": [22, 34]}, {"key": "other-technology", "type": "definition", "offset": [78, 94]}, {"key": "screening-methods", "type": "definition", "offset": [183, 200]}], "snippet": "means any Know-How or Patent Right that claims or covers a method, process or other technology generally useful for peptide synthesis, discovery, research and/or development (such as screening methods, test assays and the like).", "size": 4, "hash": "a0472f029f24d202455669bd80c623af", "id": 8}, {"samples": [{"hash": "hUNrjRqwkbk", "uri": "/contracts/hUNrjRqwkbk#platform-technology", "label": "Subscription Agreement (LumiraDx LTD)", "score": 33.544834137, "published": true}, {"hash": "iBAkCMJe6Ev", "uri": "/contracts/iBAkCMJe6Ev#platform-technology", "label": "Letter Agreement (LumiraDx LTD)", "score": 32.5126609802, "published": true}, {"hash": "b5SaI2DdeBq", "uri": "/contracts/b5SaI2DdeBq#platform-technology", "label": "Letter Agreement (LumiraDx LTD)", "score": 32.0390129089, "published": true}], "snippet_links": [{"key": "service-and-support", "type": "clause", "offset": [99, 118]}, {"key": "in-respect-of", "type": "definition", "offset": [150, 163]}, {"key": "diagnostic-tests", "type": "clause", "offset": [178, 194]}, {"key": "and-health", "type": "clause", "offset": [251, 261]}, {"key": "not-limited", "type": "clause", "offset": [310, 321]}, {"key": "related-to", "type": "definition", "offset": [337, 347]}, {"key": "management-of", "type": "clause", "offset": [385, 398]}, {"key": "related-data", "type": "definition", "offset": [438, 450]}, {"key": "quality-control", "type": "definition", "offset": [456, 471]}, {"key": "health-systems", "type": "definition", "offset": [547, 561]}, {"key": "the-platform", "type": "definition", "offset": [563, 575]}, {"key": "intellectual-property-rights", "type": "definition", "offset": [658, 686]}, {"key": "by-the-company", "type": "clause", "offset": [721, 735]}, {"key": "at-closing", "type": "definition", "offset": [772, 782]}], "snippet": "means the Company\u2019s research, development, clinical, regulatory, manufacturing, commercialization, service and support, and distribution capabilities in respect of point-of-care diagnostic tests, integrated assays, reagents, software and instruments, and health IT and care solutions. This may include, but is not limited to, technology related to the dissemination and/or storage and management of diagnostic results, associated patient-related data, and quality control related data (e.g. real-time instrument functionality and controls) within health systems. The Platform Technology includes technologies, materials, know-how, intellectual property, and intellectual property rights owned, controlled, or in licensed by the Company or its Affiliates, whether existing at closing or later developed, owned, controlled or in licensed by the Company or its Affiliates.", "size": 3, "hash": "c63fccb351b27b39c986ec96670aa7de", "id": 9}, {"samples": [{"hash": "4FqvSGxqm5s", "uri": "/contracts/4FqvSGxqm5s#platform-technology", "label": "Collaboration Agreement (Receptos, Inc.)", "score": 24.2881584167, "published": true}, {"hash": "i76fnZGQaKo", "uri": "/contracts/i76fnZGQaKo#platform-technology", "label": "Collaboration Agreement (Receptos, Inc.)", "score": 24.2553043365, "published": true}, {"hash": "3DBlbH5SLaK", "uri": "/contracts/3DBlbH5SLaK#platform-technology", "label": "Collaboration Agreement (Receptos, Inc.)", "score": 24.1184120178, "published": true}], "snippet_links": [{"key": "the-recitals", "type": "clause", "offset": [36, 48]}], "snippet": "shall have the meaning set forth in the Recitals.", "size": 3, "hash": "aed8450461c17a3cac4ce1934599e378", "id": 10}], "next_curs": "CmASWmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjwLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIccGxhdGZvcm0tdGVjaG5vbG9neSMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Platform Technology", "snippet": "means the executable form of the PressReader web building tools as such technology is revised, updated, enhanced and modified from time to time (and including in all respects all Intellectual Property Rights therein), as such exist from time to time;", "size": 89, "id": "platform-technology", "examples": ["Upon completion of preliminary due diligence by NCPS, acceptance of the Offering for placement, and commencement of the Offering Period, these materials and any other materials provided by the Company will comprise the offering materials for the Offering (the \u201cOffering Materials\u201d), which will be made available through the <strong>Platform Technology</strong>.", "The Parties recognize the need for Adimab to disclose the general capabilities of the Adimab <strong>Platform Technology</strong>.", "Pieris Controls (defined below) certain intellectual property related to Pieris\u2019 <strong>Platform Technology</strong> (defined below).", "Adimab shall have the sole right (but not the obligation) to file, prosecute, maintain, defend and enforce all Patents directed to Adimab <strong>Platform Technology</strong> and all Adimab Platform Patents, all at its own expense.", "Adimab shall solely own, regardless of inventorship, all Program Patents directed to Adimab <strong>Platform Technology</strong> Improvements and, prior to Option exercise, all Program Antibody Patents.", "As between the Parties, CRISPR will own and retain all of its rights, title and interest in and to the CRISPR Background Know-How, CRISPR Background Patents and CRISPR <strong>Platform Technology</strong> Patents and Vertex will own and retain all of its rights, title and interest in and to any Vertex Background Know-How and Vertex Background Patents, subject to any assignments, rights or licenses expressly granted by one Party to the other Party under this Agreement.", "Within thirty (30) days after the end of each half year, each Party shall provide the Patent Committee with a report listing all Patents relating to such Parties\u2019 utilization of the <strong>Platform Technology</strong> filed by that Party during that half year.", "Program Know-How that constitutes Adimab <strong>Platform Technology</strong> Improvements shall be owned by Adimab and all other Program Know-How shall be owned by the Party that created it.", "For the avoidance of doubt, the License specifically excludes the right to use the Adimab <strong>Platform Technology</strong> to discover or optimize antibodies.", "The Foundation Investment will be conditioned on the Company\u2019s receipt and continuation of all necessary licenses and rights with respect to the <strong>Platform Technology</strong> needed to perform the Global Access Commitments."], "related": [["program-technology", "Program Technology", "Program Technology"], ["product-technology", "Product Technology", "Product Technology"], ["joint-technology", "Joint Technology", "Joint Technology"], ["licensee-technology", "Licensee Technology", "Licensee Technology"], ["background-technology", "Background Technology", "Background Technology"]], "related_snippets": [], "updated": "2026-02-07T04:24:37+00:00"}, "json": true, "cursor": ""}}